NFXF Blog
Featured
The initiative will build on our 40 years of work, promoting broader use of evidence-based information among individuals with FXS, caregivers, family members, community partners, and healthcare providers nationwide.
Why Fragile X Syndrome Treatment Information Feels So Confusing
08 mins read
FXS Tips & Support for Traveling + Free Downloads
06 mins read
Advocacy is Year-Round: What That Looks Like
05 mins read
Understanding What the Texas v. Kennedy Ruling Means for Community Living
03 mins read
All Articles
Research Summary: The results found from the EEGs in both the FMR1 KO mice and humans with FXS are extremely important for the future of FXS research because they show a measurable commonality between the two very different species.
Allos Pharma announced they held a meeting with the FDA to optimize the design of their Phase 3 trial designed to support an NDA to address FXS.
RECONNECT is designed to confirm results of the first randomized, double-blind, placebo-controlled trial of ZYN002 conducted in FXS, CONNECT-FX.
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
